Simeon George, M.D. is CEO of SR One. Previously, Dr. George worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Dr. George is a co-founder and board member of Nkarta and currently serves on the boards of CRISPR Therapeutics (CRSP) and Turning Point Therapeutics (TPTX). Dr. George previously served of the boards of Principia Biopharma (PRNB), Progyny (PGNY), HTG Molecular (HTGM) and Genocea Biosciences (GNCA). Dr. George received a B.A. in neuroscience from Johns Hopkins University, where he graduated Phi Beta Kappa. He received an M.D. from the University of Pennsylvania School of Medicine and an MBA (Mayer Scholar) from the Wharton School of the University of Pennsylvania.